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Article

Multiple Versus Single Antipsychotic Agents
for Hospitalized Psychiatric Patients:
Case-Control Study of Risks Versus Benefits
Franca Centorrino, M.D.
Jessica L. Goren, Pharm.D.
John Hennen, Ph.D.
Paola Salvatore, M.D.
James P. Kelleher, M.D.
Ross J. Baldessarini, M.D.

Objective: Since use of multiple drugs to
treat psychiatric patients is increasing, and
research on this practice is rare, the authors carried out a retrospective case-control study of multiple versus single antipsychotic treatment in psychiatric inpatients.
Method: Inpatient treatment groups receiving either antipsychotic monotherapy
or polytherapy were matched in terms of
age, sex, diagnostic category, and admission clinical ratings (Global Assessment of
Functioning [GAF] and Clinical Global
Impression [CGI]), which yielded 70 subject pairs. They were compared in terms
of total chlorpromazine-equivalent daily
dose, changes in total daily dose, length
of hospitalization, incidence of adverse
effects, and changes in clinical ratings (CGI,
GAF, Positive and Negative Syndrome

Scale score) between admission and
discharge.
Results: Initial doses were closely similar
at admission for both treatment groups,
but the median total final antipsychotic
dose was 78% higher for those receiving
antipsychotic polytherapy versus monotherapy. Also, median length of stay in the
hospital was 55% (8.5 days) longer, and risk
of adverse effects was 56% higher with
polytherapy, whereas clinical improvement scores were similar (within 11%) for
both treatments.
Conclusions: Short-term treatment with
multiple antipsychotics was associated
with major increases in drug exposure, adverse events, and time in the hospital but
with no apparent gain in clinical benefit.
These findings require further testing in
controlled prospective studies.
(Am J Psychiatry 2004; 161:700–706)

A medicine…should always be presumed to be
hurtful (1).

S

imultaneous use of multiple psychotropic drugs, be
they similar or dissimilar, by patients with major psychiatric disorders is a very common clinical practice (2). Evidence that such treatment is becoming increasingly common includes a study of 178 bipolar disorder patients with
psychotic features hospitalized at the U.S. National Institute of Mental Health, in which the proportion simultaneously given three or more psychotropic medicines, including antipsychotics, increased from 3.3% in 1974–1979
to 44% in 1990–1995 (3). In that sample, length of hospitalization rose with the number of medicines prescribed at
discharge, possibly as a reflection of illness severity or
treatment unresponsiveness, whereas changes in clinical
ratings were unrelated to drug count (3). Recent studies
have found simultaneous use of more than one antipsychotic agent in 25%–50% of hospitalized psychiatric patients (4–9). In an analysis of recent antipsychotic drug use
among hospitalized patients, we found prescribing patterns that were consistent with the preceding reports in
that multiple antipsychotics were given to 43% of patients
in 1998 (compared with 6% in 1993 and 2% in 1989), with a
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corresponding 46% increase in estimated chlorpromazine-equivalent total daily dose of antipsychotic agents
between 1989 and 1998 (10).
This trend toward polytherapy with antipsychotics and
other psychotropic medicines may reflect availability of a
growing number of pharmacologically varied drugs approved by the Food and Drug Administration (FDA) with
demonstrated efficacy in major psychiatric disorders (11).
Among antipsychotic drugs, combinations of newer atypical agents with older neuroleptics appear to be especially
common (10). With chronically ill psychotic patients, who
typically show only limited benefits of treatment, simultaneous use of more than one antipsychotic agent may reflect hopes for greater effectiveness of treatment involving
drugs with somewhat dissimilar actions. However, such
practices lack compelling empirical evidence of superior
effectiveness, might compromise safety and tolerability,
and may increase the cost of care.
Potential clinical benefits associated with the use of
multiple antipsychotics have been considered in a few reports, mostly involving small case series without control
subjects (12–20). In such studies, combinations of risperidone with clozapine (12–14), loxapine with clozapine (15),
olanzapine with clozapine (16), and risperidone with
olanzapine (17), as well as various combinations of older
Am J Psychiatry 161:4, April 2004
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and modern antipsychotics (18–20), were suggested to
have favorable effects on the basis of clinical observations
of benefits not found with previous standard monotherapies. However, these open, uncontrolled clinical experiences, although provocative, do not prove that such combinations are clinically superior than or as equally well
tolerated as vigorously applied monotherapies, including
the use of older and much less expensive neuroleptics. A
rare placebo-controlled, double-blind trial found clinical
benefit in adding sulpiride over placebo to ongoing treatment with clozapine; however, this trial was small (N=28)
and did not include a control condition involving increased
doses of clozapine alone (21).
Tolerability and potential risks of adverse effects associated with antipsychotic polytherapy have received particularly limited research attention. In one report, increases in
only relatively minor adverse effects, such as excess sedation, were found with several combinations of newer and
older antipsychotic agents (22). However, a prospective,
10-year follow-up study found that overall mortality rates
among 88 hospitalized patients diagnosed with schizophrenia inexplicably were increased by two- to threefold in
association with antipsychotic polytherapy (23).
The evidently growing contemporary prevalence of antipsychotic polytherapy calls for studies of the clinical effects, medical risks, and economic costs of concurrent use
of multiple antipsychotic drugs. Accordingly, we now report on an analysis of consecutive hospitalized patients
treated with more than one antipsychotic drug at the same
time and compared this group with a matched group of
similar patients treated with only one antipsychotic drug
at any time during hospitalization.

Method
We screened the medical records of all inpatients with DSM-IV
psychotic disorders admitted to McLean Hospital during a 3month period (March–May) in 1998. Computerized prescription
drug records were used to identify “cases” given two or more antipsychotic drugs simultaneously for at least 3 consecutive days
during the index hospitalization, with no exclusion criteria applied. We then matched each case with a “comparator” subject
hospitalized within the same 3 months but treated with only one
antipsychotic drug at one time. Matching was by sex, DSM-IV category (schizophrenia or schizophreniform disorder, bipolar disorder with psychotic features, or other disorders), age (within 5
years), and illness severity at admission as estimated by two retrospective psychiatric ratings: Clinical Global Impression (CGI) (24)
(within 1 point) and Global Assessment of Functioning (GAF)
(DSM-IV, p. 32) (within 5 points).
We determined the initial, maximum, and final or discharge total daily antipsychotic dose for each subject and recorded the days
of use of each agent. In addition, the percentage increase from the
initial to maximum daily dose was computed as a within-subject
index of antipsychotic dosing. Reported doses (mg/day) were
based on conversion to the approximate daily chlorpromazine
equivalent, using recently developed conversion factors reported
elsewhere (10) for all FDA-approved antipsychotic agents.
Based on independent assessments of data provided in medical records by two clinician-investigators (J.L.G., P.S.), estimated
Am J Psychiatry 161:4, April 2004

TABLE 1. Demographic and Clinical Characteristics of
Matched Psychiatric Inpatients Receiving Multiple or Single
Antipsychotic Treatment
Patients Receiving Patients Receiving
Antipsychotic
Antipsychotic
Polytherapy
Monotherapy
(N=70)
(N=70)
N
%
N
%

Selection Factors
Sexa
Women
Men
Diagnosisa
Bipolar disorder
Psychotic disorders
Other disorders

Age (years)
Onset
Admissiona
Previous illness
Hospitalizations
Years of illness
Baseline illness ratings
CGIa
GAFa
Positive and Negative
Syndrome Scale
Total
Positive
Negative

43
27

61.4
38.6

43
27

61.4
38.6

18
44
8

25.7
62.9
11.4

18
44
8

25.7
62.9
11.4

Mean

SD

Mean

SD

22.7b
40.5

6.2
14.4

26.9
41.9

13.1
14.8

5.5
17.3

4.1
15.1

5.3
15.1

5.4
11.6

5.8
29.2

0.8
8.4

5.8
32.0

0.8
10.1

39.4
23.3
16.0

10.9
8.0
7.5

41.4
23.6
17.8

13.6
8.5
10.2

a Factor used to match subjects in
b Significantly different from the

the treatment groups.
onset age of patients receiving
antipsychotic monotherapy (z=2.19, p=0.03).

baseline and discharge ratings for the GAF, CGI, and Positive and
Negative Syndrome Scale (25) were made (with consensus ratings
in cases of discrepancies) independent of knowledge of dosing.
Percentage changes in the three clinical assessments between
hospital admission and discharge were computed for each subject. We also defined three subscales from the Positive and Negative Syndrome Scale to identify relationships of specific symptom
complexes in cases versus comparators. These ad hoc subscales
were: disorganization (Positive and Negative Syndrome Scale
items P2, N5, N7, G10, G11, G12), anxiety/agitation (P4, P7, G3,
G4, G14), and paranoia/hypervigilance (P6, G8, G9, G16).
Also from medical records data, we determined prior hospitalization count, approximate age at onset of the primary psychiatric diagnosis, length of stay (days) for the index hospitalization,
and the type and number of all other psychotropic drugs used. We
identified adverse effects recorded during hospitalization, by category, including neurological and general medical events, determined if they were present at admission or emerged during hospitalization, and supplemented this information with incident
use of drugs employed to manage extrapyramidal side effects (anticholinergics and lipophilic beta-blockers in the absence of a
cardiovascular indication). Both total adverse events and percentage of patients with at least one adverse event were recorded.
We examined factors and clinical outcomes associated with the
treatment classification (antipsychotic polytherapy versus monotherapy) other than those used to match the groups, with particular attention to contrasting antipsychotic doses (initial, maximum,
and final), incidence and types of medically adverse effects, hospital length of stay, and improvements in clinical ratings. Contrasts
between antipsychotic polytherapy cases and monotherapy comparators were carried out by using conditional logistic regression
methods for binary outcomes (adverse effects), negative binomial
regression for prior hospitalization counts, generalized leasthttp://ajp.psychiatryonline.org
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FIGURE 1. Initial, Maximum, and Final ChlorpromazineEquivalent Doses for Matched Psychiatric Inpatients Receiving Multiple or Single Antipsychotic Treatment
Patients receiving antipsychotic monotherapy (N=70)
Median Dose (mg/day in chlorpromazine equivalents)

600
Patients receiving antipsychotic polytherapy (N=70)

500

400

300

Antipsychotic Doses

200

100

0

Initial

Maximum

Final

squares regression with binomial family and log-link to estimate
relative risk for adverse effects, and generalized least-squares regression methods (Gaussian family) for the remaining outcomes
(changes in clinical rating scale scores from baseline, chlorpromazine-equivalent daily doses, and length of stay). Regression analyses included adjustment for clustering on matched pairs. For selected contrasts, several covariates were considered in additional
modeling; these included sex, current age, diagnostic category,
number of previous hospitalizations, and baseline CGI and GAF
ratings. Postmodeling chi-square tests were carried out for selected contrasts. For some bivariate comparisons involving continuous measures, Spearman rank correlations (rs) were used.
Chlorpromazine-equivalent dose and length of stay data were
positively skewed (few patients with unusually high doses and
long hospitalizations) and so were log-normalized before analysis.
We checked modeling fits using partial-residual plotting methods. Robust estimates of standard errors were obtained when
feasible.
Averaged continuous data are reported as means with standard
deviations, except for the skewed dose and length of stay data, for
which medians and standard deviations are reported. Statistical
significance required two-tailed p<0.05. Analyses employed Stata
(Stata Corp, College Station, Tex.) and Statview-5 (SAS Corp., Cary,
N.C.) microcomputer programs.

Results
A total of 140 inpatients in 70 matched pairs were studied. Matching of polytherapy cases and monotherapy
comparators was based on current age, sex, diagnostic
category, and initial GAF and CGI ratings, but not other
factors, all of which are summarized in Table 1. Of all factors considered, the only significant difference found was
that patients receving antipsychotic polytherapy were on
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average 4.2 years younger at illness onset than those receiving antipsychotic monotherapy (Table 1). On two severity indicators not used in matching, Positive and Negative Syndrome Scale scores (including total, positive, and
negative scores) and the number of prior hospitalizations,
the treatment groups did not differ at baseline (Table 1).
The total number of simultaneously administered psychotropic medicines ranged from one to seven, with polytherapy cases averaging 4.29 medications (SD=1.23) and
monotherapy comparators averaging 3.47 (SD=1.46). This
difference, while large, basically reflects the circumstance
that comparator subjects were prescribed one antipsychotic agent, while all polytherapy cases received at least
two such drugs at the same time, and six received three
different antipsychotic agents at some point during the inpatient stay.

http://ajp.psychiatryonline.org

In this sample of 140 patients hospitalized in 1998, 13
antipsychotic drugs were encountered: olanzapine (46.4%
of cases), quetiapine (33.6%), risperidone (19.3%), haloperidol (16.4%), perphenazine (16.4%), clozapine (6.4%),
thioridazine (4.3%), chlorpromazine (3.6%), fluphenazine
(3.6%), thiothixene (2.9%), and loxapine, promethazine,
and trifluoperazine (3.6% total). The overlap (total >100%
of cases) was due to polytherapy or changes in medication
during hospitalization. A large fraction (88.6% [N=124 of
140]) of all study patients received at least one atypical antipsychotic. The most frequently occurring combinations
of antipsychotic medicines were olanzapine with haloperidol (N=10), olanzapine with quetiapine (N=6), and
olanzapine with risperidone (N=6). Except for one agent,
quetiapine, polytherapy cases did not differ from monotherapy comparator patients in the types of antipsychotics
used. Quetiapine was used more frequently among those
receiving antipsychotic polytherapy (44.3% versus 22.9%)
(ratio=1.94; z=2.63, p=0.009).
Final total daily doses were higher in subjects diagnosed
with idiopathic psychotic disorders (N=44 pairs; median
dose [in chlorpromazine equivalents]=475 mg/day [SD=
402]) than in those with bipolar disorder with psychotic
features (N=18 pairs; median dose=267 mg [SD=262]) or
those with other miscellaneous diagnoses (N=8 pairs; median dose=197 mg [SD=387]). Of these dose contrasts, only
schizophrenia versus miscellaneous diagnosis subjects differed significantly (z=3.83, p<0.001). Final total chlorpromazine-equivalent doses were somewhat higher in men than
in women (median=283 mg/day [SD=393] versus median=
267 mg/day [SD=262], respectively) (z=2.57, p=0.01). After
the subjects were divided on the basis of age at admission
(median split at 38 years), older subjects received nonsignificantly lower final chlorpromazine-equivalent doses
than younger patients (median dose=334 mg/day [SD=378]
versus median=401 mg/day [SD=385]) (z=0.39, p=0.70).
As seen in Figure 1, the initial daily doses of antipsychotic drugs did not differ between the antipsychotic
Am J Psychiatry 161:4, April 2004
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TABLE 2. Treatment Characteristics of Matched Psychiatric Inpatients Receiving Multiple or Single Antipsychotic Treatment

Treatment Characteristic
Antipsychotic dose (mg/day in chlorpromazine equivalents)
Initial
Maximum
Final
Increase from initial dose (%)
Hospitalization (days)

Patients Receiving
Antipsychotic
Polytherapy (N=70)
Median
SD

Patients Receiving
Antipsychotic
Monotherapy (N=70)
Median
SD

200
534
475
461
24.0

201
268
267
92
15.5

Mean
Other psychotropic agents (number/subject)b
Change in clinical ratings (%)
CGI
GAF
Positive and Negative Syndrome Scale score

2.29
–28.2
–71.0
–37.0
N

Adverse effectsc

28

326
425
413
752
31.1
SD
1.23
14.0
59.8
36.6
%
40.0

Mean
2.47
–25.3
–66.7
–41.4
N
18

287
308
315
187
16.2

Analysis
Ratio

z

p

0.99
1.99
1.78
5.01
1.55

0.92
4.69
4.63
4.64
3.90

0.36
<0.001
<0.001
<0.001a
<0.001a

0.93

–0.80

0.42

1.11
1.06
0.89

–1.22
0.52
0.70

0.22
0.60
0.49

1.56

1.64

0.11a

SD
1.46
15.0
69.1
31.5
%
25.7

a

After adjustment for sex, age, diagnosis, CGI and GAF ratings at admission, and number of previous hospitalizations, the following betweengroup differences were found: log-% increase in antipsychotic dose (z=4.19, p<0.001), log-days in hospital (z=4.08, p<0.001), and risk of adverse effects (z=1.82, p<0.07).
b Includes antidepressants, anxiolytics, sedatives, and mood stabilizers.
c Patients who either had one or more adverse effects or were given additional medication for extrapyramidal symptoms.

polytherapy and monotherapy groups, but the maximum
and final total antipsychotic doses were substantially
greater in polytherapy cases (99% and 78% higher, respectively) (Table 2). Moreover, the corresponding increase
over initial doses during hospitalization was 5.0 times
greater for polytherapy cases (461%) than the monotherapy comparison patients (92%). After adjusting for sex,
age, diagnosis, admission CGI and GAF ratings, and number of previous hospitalizations, the log-% increase in
dose of antipsychotics remained significantly different between polytherapy and monotherapy subjects (Table 2).
An important consideration was that the total number
of nonantipsychotic psychotropic agents per subject
(about two) did not differ between antipsychotic polytherapy and monotherapy subjects (Table 2). Specifically, the
proportion of cases versus comparators given sedativeanxiolytics (67.1% versus 72.9%) (χ2=0.54, df=1, p=0.46),
anticonvulsants or lithium (60.0% versus 60.0%), or antidepressants (55.7% versus 57.1%) (χ2=0.03, df=1, p=0.86)
did not differ between those treated with antipsychotic
polytherapy versus monotherapy.

Risks of Adverse Effects
Most of the adverse effects encountered involved
movement disorders (bradykinesia or tremor, dyskinesia,
akathisia), with a slight excess among polytherapy cases
versus monotherapy comparators: 30.0% versus 24.3%, respectively, had evidence of at least one type of extrapyramidal dysfunction (χ2=0.58, df=1, p=0.45), whereas the incidence of all extrapyramidal dysfunctions was 42.9%
versus 30.0% (relative risk=1.43; χ2=2.50, df=1, p=0.11).
The incidence of at least one adverse effect or use of an adAm J Psychiatry 161:4, April 2004

ditional agent to treat adverse extrapyramidal effects was
somewhat higher among polytherapy cases than among
monotherapy comparators (40.0% versus 25.7%) (Table 2).
After adjusting for sex, age, diagnosis, admission CGI and
GAF ratings, and number of previous hospitalizations, the
risk of extrapyramidal effects was nearly significantly
greater with polytherapy. Use of agents intended to limit
extrapyramidal dysfunctions (centrally active anticholinergics and beta-blockers) also was only slightly greater
among polytherapy cases (32.9% versus 24.3%).
Risk of reported side effects was correspondingly greater
with higher antipsychotic final daily dose in the polytherapy cases, although not statistically significant. Patients
with above-median chlorpromazine-equivalent doses experienced adverse effects significantly more frequently
(42.6% [N=29 of 68]) than those given lower doses (23.6%
[N=17 of 72]) (relative risk=1.81; z=2.15, p<0.04). Risk of adverse effects also was clearly greater with typical neuroleptics (48.5% [N=33 of 68]) than atypical antipsychotics
(30.6% [N=38 of 124]) (relative risk=1.58; χ2=9.57, df=1, p=
0.002). Haloperidol was especially strongly associated with
adverse effects: 56.5% (N=13 of 23) given this neuroleptic
experienced adverse effects whereas only 28.2% (N=33 of
117) not exposed to haloperidol did (relative risk=2.00; z=
3.03, p=0.002). Adverse effects were somewhat more common among women (37.2% [N=32 of 86]) than men (25.9%
[N=14 of 54]) (relative risk=1.44; z=1.57, p=0.12) but did not
vary with diagnostic category or age (data not shown).

Length of Hospitalization
Median length of stay during the index hospitalization
(Table 2) was 55% (8.5 days) longer in the polytherapy
http://ajp.psychiatryonline.org
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cases, and mean length of stay was 81% longer (34.3 versus
19.0 days) (z=3.90, p<0.001). As expected, length of stay
was longer with inferior admission GAF ratings overall (rs=
–0.17, p<0.05) and with higher initial total scores on the
Positive and Negative Syndrome Scale (rs=0.20, p<0.02)
but was uncorrelated with prior hospitalization count (rs=
0.09, p=0.32). Patients experiencing adverse effects spent
on average about 4.5 days longer in hospital (26% more
days) than those without such complications (median
length of stay=22.5 days [SD=31.5] versus 17.0 days [SD=
22.2]) (z=1.91, p=0.057). Length of stay was correlated with
the maximum total antipsychotic daily dose (rs =0.17,
p<0.05) but not with the total number of psychotropic
agents prescribed (rs=0.03, p=0.73).
As suggested by the substantially larger mean than median length of stay in both treatment groups, some patients experienced unusually prolonged hospitalizations,
which were most extreme (>100 days) in six polytherapy
cases, considered statistical “outliers.” When they and
their matching monotherapy comparators were excluded,
the finding of longer length of stay with polytherapy was
sustained (median=23.0 days [SD=18.6] versus 16.0 days
[SD=12.8]) (z=3.50, p<0.001). Moreover, after adjusting for
sex, age, diagnosis, admission CGI and GAF ratings, and
number of previous hospitalizations, the difference in loglength of stay between treatment groups was again sustained (z=4.08, p<0.001).

Clinical Changes
In contrast to major excesses of maximum and final total antipsychotic doses, increases in antipsychotic total
daily doses during hospitalization, hospital length of stay,
and increased risks of adverse effects among the polytherapy cases, clinical ratings indicated very similar improvements between admission and discharge in both treatment groups. That is, percentage improvements in CGI
and GAF ratings and Positive and Negative Syndrome
Scale score all were within 11% between patients given
single or multiple antipsychotic treatment (Table 2). After
adjusting for sex, age, diagnosis, admission CGI and GAF
score, and number of previous hospitalizations, the percentage change in Positive and Negative Syndrome Scale
total score remained nonsignificant (z=0.76, p=0.45).
Moreover, changes in score on the positive or negative
symptom subscales of the Positive and Negative Syndrome
Scale and scores on the agitation, paranoia, and disorganization subscales all were similar between cases and comparators (data not shown). This similarity in clinical outcomes at hospital discharge following use of antipsychotic
monotherapy and polytherapy may well reflect clinical decisions associated with adjusting treatment and time in
the hospital to meet the requirements or responses of individual patients, and therefore is not surprising.
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Discussion
Principal findings in this retrospective case-control
comparison of psychiatric inpatients receiving antipsychotic monotherapy versus polytherapy, based on chart
reviews, include the following points. 1) Maximum and final total chlorpromazine-equivalent antipsychotic doses,
as well as the percentage increase in total daily doses during hospitalization, all were much higher among polytherapy patients. 2) Adverse effects occurred more frequently
among polytherapy patients in association with higher total antipsychotic doses. 3) Hospitalization was much
longer in antipsychotic polytherapy cases, particularly
among patients with adverse effects. 4) Clinical outcomes,
based on changes in CGI and GAF ratings and Positive and
Negative Syndrome Scale score, did not differ between the
matched treatment groups even after adjustment for age,
sex, diagnosis, and initial CGI and GAF ratings. 5) Patients
treated with antipsychotic monotherapy or polytherapy
did not differ in the total number, or types, of other coadministered psychotropic agents. 6) Patients treated with
antipsychotic polytherapy were 4.2 years younger at age at
onset of illness than those treated with antipsychotic
monotherapy. Too few patients were enrolled to make
valid comparisons in outcomes associated with specific
antipsychotic agents.
These findings are based on relatively brief inpatient
treatment, when use of multiple agents of the same type
is most likely to occur, and may not generalize to other
circumstances (3–7). In this setting, several summary
measures of clinical change during hospital stays lasting a
median of 20 days (SD=25.9) did not differ between the
antipsychotic polytherapy and monotherapy groups,
whereas hospitalization was more than a week longer
with polytherapy. The findings suggest a lack of obvious
“benefit” of inpatient antipsychotic polytherapy in either
superior clinical outcomes or shorter hospitalizations.
Moreover, the relevant “costs” include a somewhat greater
clinical burden of adverse effects, as well as the burden of
inconvenience, life disruption, and substantial added financial costs associated with longer hospitalizations
among the polytherapy cases as well as the higher drug
acquisition costs involved. However, younger age at onset
in the polytherapy group may represent a population that
is more severely ill with a longer duration of illness and
decreased medication responsiveness that may tend to
encourage use of multiple antipsychotics.
It is somewhat reassuring that the clinical burden of adverse effects associated with antipsychotic polytherapy
did not include severe or life-threatening adverse events,
probably reflecting the relative safety of modern antipsychotic agents, as well as the limited exposure involved in
this study of 140 patients during relatively brief hospitalizations (about 3,700 person-days). Nevertheless, some
adverse effects associated with modern and traditional
antipsychotic agents are not clinically trivial (e.g., acute
Am J Psychiatry 161:4, April 2004
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and later extrapyramidal reactions, hypotension with falls
and injuries or cardiovascular events, and weight gain
with potentially increased risk of diabetes and other longterm cardiovascular risks). Some are even life-threatening
(particularly the neuroleptic malignant syndrome and its
apparent variants associated even with modern drugs [11,
26, 27]). While this study did not demonstrate a difference
in serious adverse event rates, the number of participants
was too low to detect a difference in such uncommon
events. Accordingly, the safety of polytherapy remains to
be proven.
The present findings accord very closely with those of
at least one previous retrospective study (3), in which
longer hospital stays and no clear evidence of differential
clinical benefit were found in inpatients treated with multiple versus single psychotropic agents. Both investigations provide no evidence for substantial gains in benefit
(such as superior improvements on standard clinical rating scales), and both indicate a pronounced association
of psychotropic polytherapy with longer hospitalization.
In addition, we report a nearly significant association of
polytherapy with incidence of adverse effects and a correlation of adverse effects with extended length of stay. Yet,
caution is required, since an appropriate interpretation of
the findings exceeds the limits of the study design, particularly regarding the critical question of how to account
for the longer hospitalizations associated with use of antipsychotic polytherapy. Nevertheless, since both adverse
events and length of stay were closely correlated with the
total daily doses of antipsychotics involved with polytherapy, it may be that extra days in the hospital, in part, are
occasioned by management of iatrogenic side effects of
the more complex treatment.
However, another plausible interpretation is that selection of antipsychotic polytherapy, and the associated
longer hospitalization, may both represent responses to
patients with less treatment-responsive conditions. Although subjects were closely matched on several baseline
demographic and clinical variables, such factors would
not necessarily predict individual responsiveness to treatment. The design of the present study does not allow determination of reasons for electing use of antipsychotic
polytherapy nor does it avoid the issue through random
assignment to treatment options. Also, clinical decisions
about the degree of improvement required for discharge
were uncontrolled, and the study method did not permit
monitoring rates of improvement per time. These are all
limitations inherent in the retrospective-naturalistic character of this investigation. Moreover, the study size is limited, even though much larger than several earlier case series involving combinations of antipsychotic drugs (4–7).
Future studies aimed at examining outcomes associated
with multiple versus single medication treatment ideally
should employ random assignment to fixed and comparable alternative regimens, with efforts to control additional
Am J Psychiatry 161:4, April 2004

adjunctive pharmacological and psychosocial components of treatment. Such requirements obviously are not
easily attained, and such studies are not likely to receive
support from the pharmaceutical industry, since multiple
proprietary products are involved. A potentially informative, if scientifically less satisfactory, alternative to randomized studies would be large, prospective, naturalistic
studies that systematically acquire data on dosing, adverse events, and clinical outcomes during the elective use
of regimens of varied complexity.
In conclusion, there is currently no empirical foundation
for the evidently increasingly common clinical practice of
combining antipsychotic drugs in the short- or long-term
treatment of severely mentally ill patients. The consequences of this practice, even in short-term use, are uncertain, although the present findings do not indicate a favorable cost/benefit relationship for hospitalized and mainly
psychotic or manic patients. The unknown potential for
adverse long-term iatrogenic effects of antipsychotic polytherapy, and of psychiatric polytherapy in general, is of
even greater concern. The practice appears to arise from
the unwarranted, and potentially harmful, presumption
that greater benefits should be achieved with more aggressive treatment at minimal or no extra risk or cost.
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